Telix Pharmaceuticals Ltd — Capital/Financing Update 2019

Oct 28, 2019

Telix Pharmaceuticals Limited ACN 616 620 369 Suite 401, 55 Flemington Road North Melbourne Victoria, 3051 Australia

==> picture [147 x 81] intentionally omitted <==

TLX591-CDx (Marketed as illumet[TM] in the United States) Sales Note to Accompany Appendix 4C

➢ Strong quarter of kit sales ➢ Q3 Orders up by 20% over Q2 ➢ ~8,200 patient doses produced YTD

Melbourne (Australia) – 29 October 2019. Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Group”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularlytargeted radiation” (MTR), today provides a sales update for the TLX591-CDx ([68] Ga-PSMA11) kit, marketed in the United States as illumet[TM] (“Kit”).

In calendar Q3 (July-Sept) the Group booked orders worth A$1.44m (compared with A $1.2m in the previous quarter) with A$934,000 cash reported in the Group’s Appendix 4C. The difference between booked orders value and cash is attributable to payment terms on invoices (typically 60 days) and a significant number of Kit orders were back-ended in the quarter because of the impact of northern hemisphere summer holidays. The Group also carries A$535,000 of aged debtors, mostly European public hospitals.

This growth represents a 20% increase in sales of Kits (and related revenues) over the previous quarter. Approximately 75% of Kits were sold for investigational or special access use and the remainder as part of clinical collaborations with leading academic centres and pharma collaborators around the globe. Pricing for Kits has remained stable. YTD, over 8,000 patient doses of 68Ga-PSMA have been produced by licensed clinical sites and radiopharmacies using the Kit.[1]

Telix CEO Dr. Christian Behrenbruch stated, “we continue to make good progress in globally developing a customer base for our prostate imaging product, in advance of our planned US/EU market launch in 2020.[2] There is a growing appreciation of the quality and ease-of-use of the product, and opinion leader traction at the recent European Association of Nuclear Medicine (EANM) congress put a significant spotlight on our product development activity.”

TLX591-CDx ( illumet[TM] ) is commercially available as a “cold kit” for the preparation of 68Ga-PSMA-11 for the imaging of metastatic prostate cancer. The Kit is available for use on a limited basis as an investigational product for an authorised clinical trial (US) on a named patient basis (EU/UK), Special Access Scheme (Australia) or compassionate use (RoW).

TLX591-CDx has not received a marketing authorisation in any jurisdiction.

1 The TLX591-CDx/ illumetTM kit is designed to be used as a multi-dose kit (up to 50mCi of activity). In the US, a kit is typically used to produce a single dose. In the Europe the average number of doses/kit is currently 2.5, based on prevailing[68] Ga generator specifications.

2 Subject to US and EU regulatory approvals

Page 1

Confidential

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited (“Telix”) is a global biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR). The company is headquartered in Melbourne with international operations in Brussels (EU), Kyoto (JP) and Indianapolis (US). Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer. Telix is listed on the Australian Securities Exchange (ASX:TLX). For more information visit www.telixpharma.com.

Telix Corporate Contact

Dr Christian Behrenbruch Telix Pharmaceuticals Limited CEO Email: chris@telixpharma.com

Telix Investor Relations

Dr. David Cade Telix Pharmaceuticals Limited CBO and Head of Investor Relations Email: david.cade@telixpharma.com

Important Information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the “US Securities Act”), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available. None of the products described in this release have obtained a marketing authorisation in any jurisdiction.

Page 2